Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Protagonist Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PTGX
Nasdaq
8731
https://www.protagonist-inc.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Protagonist Therapeutics Inc
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data
- Mar 26th, 2024 11:00 am
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
- Mar 18th, 2024 1:55 pm
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda
- Mar 18th, 2024 11:00 am
Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year
- Mar 11th, 2024 11:00 am
Protagonist Therapeutics to Participate in Upcoming Investor Conferences
- Mar 6th, 2024 9:05 pm
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
- Mar 5th, 2024 9:43 am
This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year
- Mar 3rd, 2024 12:46 pm
Earnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their Estimates
- Mar 2nd, 2024 12:24 pm
Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?
- Mar 1st, 2024 5:20 pm
Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice
- Mar 1st, 2024 5:00 pm
Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?
- Mar 1st, 2024 5:00 pm
Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade
- Mar 1st, 2024 2:55 pm
Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why
- Mar 1st, 2024 1:50 pm
Protagonist Therapeutics Full Year 2023 Earnings: Beats Expectations
- Mar 1st, 2024 10:36 am
We're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn
- Feb 29th, 2024 10:05 am
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Feb 27th, 2024 9:05 pm
New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera
- Feb 21st, 2024 10:00 pm
Protagonist Therapeutics Reports Granting of Inducement Awards
- Feb 20th, 2024 9:05 pm
Steven Cohen Adjusts Position in Protagonist Therapeutics Inc
- Feb 15th, 2024 8:13 am
New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study
- Feb 7th, 2024 10:00 pm
Scroll